Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Hematopoietic Neoplasm
Interventions
DRUG

SAR302503

"Pharmaceutical form:capsule~Route of administration: oral"

Trial Locations (42)

1090

Investigational Site Number 040001, Vienna

2060

Investigational Site Number 056002, Antwerp

3000

Investigational Site Number 056003, Leuven

5020

Investigational Site Number 040002, Salzburg

10021

Investigational Site Number 840009, New York

10032

Investigational Site Number 840018, New York

13273

Investigational Site Number 250001, Marseille

20122

Investigational Site Number 380001, Milan

21100

Investigational Site Number 380003, Varese

21201

Investigational Site Number 840017, Baltimore

21229

Investigational Site Number 840013, Baltimore

28222

Investigational Site Number 724003, Majadahonda

29406

Investigational Site Number 840024, Charleston

30029

Investigational Site Number 250003, Nîmes

30322

Investigational Site Number 840005, Atlanta

31000

Investigational Site Number 250004, Toulouse

37007

Investigational Site Number 724002, Salamanca

39120

Investigational Site Number 276006, Magdeburg

44195

Investigational Site Number 840022, Cleveland

45042

Investigational Site Number 840019, Middletown

50134

Investigational Site Number 380004, Florence

60590

Investigational Site Number 276003, Frankfurt am Main

60637

Investigational Site Number 840014, Chicago

68167

Investigational Site Number 276001, Mannheim

75475

Investigational Site Number 250002, Paris

75571

Investigational Site Number 250006, Paris

77030

Investigational Site Number 840002, Houston

85054

Investigational Site Number 840007, Phoenix

89081

Investigational Site Number 276005, Ulm

94143

Investigational Site Number 840003, San Francisco

Investigational Site Number 840004, San Francisco

66160-7321

Investigational Site Number 840001, Kansas City

48109-0759

Investigational Site Number 840010, Ann Arbor

84112-5550

Investigational Site Number 840015, Salt Lake City

M5G 2M9

Investigational Site Number 124001, Toronto

04103

Investigational Site Number 276007, Leipzig

00161

Investigational Site Number 380002, Roma

1081 HV

Investigational Site Number 528002, Amsterdam

6229 HX

Investigational Site Number 528003, Maastricht

6525 GA

Investigational Site Number 528001, Nijmegen

08036

Investigational Site Number 724001, Barcelona

SE1 9RT

Investigational Site Number 826001, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY